Atopic Dermatitis Drug Maintained Skin Clearance Results
Three-year study data show consistent symptom relief for adolescents and adults with atopic dermatitis.
Updated on Oct. 14, 2026 in Asthma
Live Poll
Would you trust a newly approved medication based on three-year clinical trial results?
Galderma has released three-year clinical trial results for NEMLUVIO, showing sustained skin clearance and itch reduction in patients with atopic dermatitis. The ARCADIA LTE study tracked 295 early responders, with a majority reporting significant improvements in skin health and quality of life over the 152-week period.
Why it matters
Long-term data are critical for understanding whether initial treatment success for chronic skin conditions like atopic dermatitis can be maintained over several years. These findings offer insights into the durability of the medication for adolescents and adults managing the condition.
In the ARCADIA LTE study of 295 early responders, 80% of patients achieved EASI-90 improvement and 76% achieved IGA 0/1 skin status by Week 152. Additionally, an interim analysis of 1,903 patients showed 91% achieved EASI-75, with no new safety signals reported during the three-year duration.
The players
Galderma
A pharmaceutical company focused on dermatological treatments and skin health products.
The details
The study utilized maintenance and extension phases to monitor patients aged 12 and older who showed early response to the treatment. Investigators assessed skin severity through the Investigator Global Assessment (IGA) scale and the Eczema Area and Severity Index (EASI), measuring long-term disease control and patient-reported quality of life. The treatment protocol showed sustained efficacy in reducing inflammation and pruritus throughout the 152-week observation period.
Timeline
Week 16: Initial patient response measurement
Week 52: Pediatric data collection for ages 2 to 11
Week 56: Skin clearance and severity improvement measurements
Week 148: Prurigo nodularis burden improvement measurements
Week 152: Three-year long-term efficacy measurement
Health Landscape
The ARCADIA LTE study provides data that extends the current understanding of long-term biologic therapy for atopic dermatitis. These results mark a progression from short-term symptom relief toward demonstrating durable disease control in chronic inflammatory skin conditions.
If you are managing atopic dermatitis, these findings emphasize the importance of tracking long-term skin health with your dermatologist to determine if your treatment plan is meeting your goals. Discussing how clinical trial outcomes compare to your personal skin severity trends is a conversation to have with your physician.
The takeaway
The study suggests that long-term efficacy for skin clearance is possible for many patients with atopic dermatitis. Track your symptoms and skin status consistently, and talk to your doctor about whether your current long-term maintenance plan is meeting your quality-of-life needs.
Further reading
Learn more about the latest research and management strategies for this condition in our Asthma section.
Live Poll
Would you trust a newly approved medication based on three-year clinical trial results?
